Abstract
Prion (PrPC) is an endogenous protein found mainly in the nervous system, and its misfolded isoform (PrPSc) is associated with a group of neurodegenerative disorders known as transmissible spongiform encephalopathies, or simply prion diseases. The PrPSc isoform shows an intriguing ability to self-perpetuate, acting as template for PrPC misfolding and consequent aggregation. Aggregation in vitro and in vivo follows a fibrillation processes that is associated with neurodegeneration. Therefore, it is important to investigate and understand the molecular mechanisms involved in this process; such understanding also allows investigation of the action of possible candidate molecules to inhibit this process. Here, we highlight useful in vitro methodologies and analyses that were developed using PrP as a protein model but that, as other amyloid proteins also exhibit the same behavior, may be applied to understand other “prion-like” diseases such as Alzheimer’s and Parkinson’s disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95(23):13363–13383. https://doi.org/10.1073/pnas.95.23.13363
Silva JL, Cordeiro Y (2016) The “Jekyll and Hyde” actions of nucleic acids on the prion-like aggregation of proteins. J Biol Chem 291(30):15482–15490. https://doi.org/10.1074/jbc.R116.733428
Eraña H, Venegas V, Moreno J, Castilla J (2017) Prion-like disorders and transmissible spongiform Encephalopathies: an overview of the mechanistic features that are shared by the various disease-related misfolded proteins. Biochem Biophys Res Commun 483(4):1125–1136. https://doi.org/10.1016/j.bbrc.2016.08.166
Soto C (2012) Transmissible proteins: expanding the prion heresy. Cell 149(5):968–977. https://doi.org/10.1016/j.cell.2012.05.007
Rangel LP, Costa DCF, Vieira TCRG, Silva JL (2014) The aggregation of mutant p53 produces prion-like properties in cancer. Prion 8(1):75–84. https://doi.org/10.4161/pri.27776
Morris AM, Watzky MA, Finke RG (2009) Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim Biophys Acta 1794(3):375–397. https://doi.org/10.1016/j.bbapap.2008.10.016
Vieira TC, Cordeiro Y, Caughey B, Silva JL (2014) Heparin binding confers prion stability and impairs its aggregation. FASEB J 28(6):2667–2676. https://doi.org/10.1096/fj.13-246777
Ferreira NC, Ascari LM, Hughson AG, Cavalheiro GR, Góes CF, Fernandes PN, Hollister JR, da Conceição RA, Silva DS, Souza AMT, Barbosa MLC, Lara FA, Martins RAP, Caughey B, Cordeiro Y (2017) A promising anti-prion trimethoxychalcone binds to the globular domain of PrPC and changes its cellular location. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01441-17
Ferreira NC, Marques IA, Conceição WA, Macedo B, Machado CS, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, Nunes RJ, Hughson AG, Raymond LD, Pascutti PG, Caughey B, Cordeiro Y (2014) Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches. PLoS One 9(1):e84531. https://doi.org/10.1371/journal.pone.0084531
Burchell JT, Panegyres PK (2016) Prion diseases: immunotargets and therapy. Immunotargets Ther 5:57–68. https://doi.org/10.2147/ITT.S64795
Martins PM (2013) True and apparent inhibition of amyloid fibril formation. Prion 7(2):136–139. https://doi.org/10.4161/pri.23111
Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL (2001) Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 40(20):6036–6046. https://doi.org/10.1021/bi002555c
Kamal Zaidi F, Bhat R (2018) Resveratrol interferes with an early step in the fibrillization pathway of human lysozyme and modulates it towards less-toxic, off-pathway aggregates. Chembiochem 19(2):159–170. https://doi.org/10.1002/cbic.201700207
Hyeon JW, Kim SY, Lee SM, Lee J, An SS, Lee MK, Lee YS (2017) Anti-prion screening for Acridine, dextran, and tannic acid using real time-quaking induced conversion: a comparison with PrPSc-infected cell screening. PLoS One 12(1):e0170266. https://doi.org/10.1371/journal.pone.0170266
Wilham JM, Orru CD, Bessen RA, Atarashi R, Sano K, Race B, Meade-White KD, Taubner LM, Timmes A, Caughey B (2010) Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog 6(12):e1001217. https://doi.org/10.1371/journal.ppat.1001217
Schmitz M, Cramm M, Llorens F, Müller-Cramm D, Collins S, Atarashi R, Satoh K, Orrù CD, Groveman BR, Zafar S, Schulz-Schaeffer WJ, Caughey B, Zerr I (2016) The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases. Nat Protoc 11(11):2233–2242. https://doi.org/10.1038/nprot.2016.120
Baskakov IV, Bocharova OV (2005) In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features. Biochemistry 44(7):2339–2348. https://doi.org/10.1021/bi048322t43
Bocharova OV, Breydo L, Salnikov VV, Gill AC, Baskakov IV (2005) Synthetic prions generated in vitro are similar to a newly identified subpopulation of PrPSc from sporadic Creutzfeldt-Jakob disease. Protein Sci 14(5):1222–1232. https://doi.org/10.1110/ps.041186605
Naiki H (2017) Thioflavin T: not an all-rounder, but a trustworthy friend for over 27 years. Amyloid 24(sup1):9. https://doi.org/10.1080/13506129.2017.1278688
Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, Arnsdorf MF, Lindquist SL (2000) Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289(5483):1317–1321. https://doi.org/10.1126/science.289.5483.1317
Lee J, Culyba EK, Powers ET, Kelly JW (2011) Amyloid-Œ≤ forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 7(9):602–609. https://doi.org/10.1038/nchembio.624
Nizynski B, Dzwolak W, Nieznanski K (2017) Amyloidogenesis of tau protein. Protein Sci 26(11):2126–2150. https://doi.org/10.1002/pro.3275
Acknowledgments
We are thankful to Lucas M. Ascari (Faculty of Pharmacy-UFRJ) for revision of the in vitro-produced fibril assay.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Vieira, T.C.R.G., Silva, J.L. (2019). In Vitro Prion Amplification Methodology for Inhibitor Screening. In: Gomes, C. (eds) Protein Misfolding Diseases. Methods in Molecular Biology, vol 1873. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8820-4_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8820-4_20
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8819-8
Online ISBN: 978-1-4939-8820-4
eBook Packages: Springer Protocols